Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease

A 45-year-old, non-smoker woman with a previous medical history of allergic asthma presented with progressive dyspnea in October 2015. The chest X-ray and computed tomography (CT) showed bilateral reticulonodular opacities, an opacification on the right inferior lobe and ipsilateral malignant pleural effusion confirmed by thoracocentesis (Fig. 1A –C). A bronchial biopsy showed lung adenocarcinoma with anaplastic lymphoma kinase (ALK) rearrangement by fluorescence in situ hybridization. The patient started front-line crizotinib 250 mg twice daily (bid) and nine days later, she went to the emergency unit complaining of worsening dyspnea an d fever, with no other respiratory or heart failure symptoms.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research